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Summary
Background The effectiveness and cost-effectiveness of biologic therapies for psoria-
sis are significantly compromised by variable treatment responses. Thus, more
precise management of psoriasis is needed.
Objectives To identify subgroups of patients with psoriasis treated with biologic
therapies, based on changes in their disease activity over time, that may better
inform patient management.
Methods We applied latent class mixed modelling to identify trajectory-based patient
subgroups from longitudinal, routine clinical data on disease severity, as measured
by the Psoriasis Area and Severity Index (PASI), from 3546 patients in the British
Association of Dermatologists Biologics and Immunomodulators Register, as well
as in an independent cohort of 2889 patients pooled across four clinical trials.
Results We discovered four discrete classes of global response trajectories, each char-
acterized in terms of time to response, size of effect and relapse. Each class was associ-
ated with differing clinical characteristics, e.g. body mass index, baseline PASI and
prevalence of different manifestations. The results were verified in a second cohort of
clinical trial participants, where similar trajectories following the initiation of
biologic therapy were identified. Further, we found differential associations of the
genetic marker HLA-C*06:02 between our registry-identified trajectories.
Conclusions These subgroups, defined by change in disease over time, may be
indicative of distinct endotypes driven by different biological mechanisms and
may help inform the management of patients with psoriasis. Future work will
aim to further delineate these mechanisms by extensively characterizing the sub-
groups with additional molecular and pharmacological data.
What is already known about this topic?
• While many patients with psoriasis respond to treatment with biologics, there are
those who show little or no response and those who respond initially but then
either lose response or suffer from adverse effects.
© 2021 The Authors. British Journal of Dermatology
published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists
British Journal of Dermatology (2021) 1
This is an open access article under the terms of the Creative Commons Attribution License, which permits use,
distribution and reproduction in any medium, provided the original work is properly cited.
• Better characterization of patients who will, or will not, benefit from biologic ther-
apy will facilitate the understanding of relevant biological mechanisms and explain
treatment outcome variation in patient cohorts.
What does this study add?
• Using a data-driven approach, we identified four subgroups of patients with psori-
asis defined by global trajectories of response to biologic therapies.
• Our results were replicated in a second cohort obtained by pooling data from four
clinical trials of biologic therapies for psoriasis.
• We further identified potential human leucocyte antigen biomarkers that help to
distinguish between the trajectory-based subgroups.
Biologic therapies have revolutionized outcomes for people
with severe psoriasis. However, these drugs are expensive and
while many patients respond well to treatment there are sub-
groups who are considered ’primary failures’ or secondary
(responding initially but then losing response) failures, or
who suffer adverse effects.1,2 A recent network meta-analysis
of 41 randomized controlled trials indicated significant hetero-
geneity in response between biologics for psoriasis with
respect to effectiveness and tolerability;3 however, traditional
methods used to understand this heterogeneity in response
have largely been uninformative.4–6
Relatively little attention has been paid to the trajectories of
disease progression and treatment response, which may differ
greatly between patients. For example, the examination of
response trajectories to clozapine in a secondary analysis of
pivotal trials has supported the use of treatment-response tra-
jectories to subtype patients with schizophrenia;7 and a simple
post hoc analysis of methotrexate trial data hints at subtypes
of response in psoriasis with the description of ‘early’ and
‘late’ responders.8
With the vision of the Psoriasis Stratification to Optimise
Relevant Therapy (PSORT) consortium being to further per-
sonalized medicine in psoriasis by gaining a better under-
standing of the global patterns of disease,9 we took a data-
driven approach with an unsupervised statistical learning
method to identify latent classes, or subgroups, of patients
with psoriasis that display similar patterns of disease severity
over time (i.e. trajectories) following biologic treatment.
Latent class mixed modelling (LCMM) has previously been
successful in the identification of patterns of predisease obesity
in type 2 diabetes.10 Here, we applied latent class trajectory
analysis to analyse a large-scale, longitudinal, patient-level,
real-world, cohort – the British Association of Dermatologists
Biologics and Immunomodulators Register (BADBIR) – to test
(i) whether we could identify universal subgroups of patients
with psoriasis with distinct patterns of change in disease fol-
lowing the initiation of biologic therapies; (ii) assess baseline
characteristics and differences between identified subgroups;
(iii) identify differential risk of treatment failure that is
associated with the identified trajectory subgroups; and (iv)
determine the association of any identified subgroups with a
known genetic marker (HLA-C*06:02). We validated this
approach by identifying similar trajectory-based subgroups in
a second, independent cohort of patients with psoriasis treated
with biologic therapies in clinical trials.
Materials and methods
British Association of Dermatologists Biologics and
Immunomodulators Register participants and data
All data were obtained from BADBIR,11 which is a large
prospective observational register of adults with psoriasis trea-
ted with either biologic therapies or nonbiological systemic
therapies. It was established with the aim of evaluating the
long-term, real-world safety of biologics in the treatment of
psoriasis. Following registration and acquisition of baseline
data, changes in therapy, disease activity and adverse events
are recorded for each patient (6-monthly for 3 years, then
annually).
Of 10 638 registered patients with psoriasis from 152
dermatology departments in the UK and Ireland, in the per-
iod of March 2007–August 2015, 3546 fulfilled the inclu-
sion criteria. These were patients (i) receiving their first
biologic therapy [including the tumour necrosis factor
(TNF) inhibitors adalimumab, etanercept and infliximab,
and the interleukin (IL)-12/IL-23 inhibitor ustekinumab;
Table 1 and Figure 1]; (ii) with a baseline Psoriasis and
Area Severity Index (PASI) measurement ≥ 10, signifying
moderate-to-severe psoriasis; and (iii) with complete base-
line data (no minimal follow-up required). A total of 12
751 observations (PASI) were included (7429 adalimumab;
2938 etanercept; 264 infliximab; and 2120 ustekinumab).
The number of PASI measurements per patient ranged from
1 to 17, with a mean (SD) of 36 (25); and a mean (SD)
follow-up of 12 (10) years (interquartile range 0–21) –
these were sufficient to derive response trajectories using
LCMMs.
© 2021 The Authors. British Journal of Dermatology
published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists
British Journal of Dermatology (2021)
2 Trajectories of response in patients with psoriasis treated with biologics, N. Geifman et al.
Latent class mixed models
LCMM is a type of latent class analysis that identifies unmea-
sured class membership among subjects using observed cate-
gorical and/or continuous variables, and includes a random
intercept and random coefficients for each individual; it is
used to identify meaningful subgroups with homogeneous
pattern of change over time.
In this study, we specified LCMMs with PASI as the depen-
dent/outcome variable. Mixed effects were used to account
for the likely correlation of repeated measurements within the
same patient and included a random intercept for each indi-
vidual. In all the models, we assumed the effects of included
potential confounders to be the same for all latent classes and
aimed to identify latent classes with different regression
parameters vs. time.
In each case, we tested the model for 1–10 latent classes
and the optimal number of latent classes was assessed using
the Bayesian Information Criterion (BIC); the model with the
lowest BIC and at least 5% of patients in all the resulting
Table 1 Baseline characteristics, and 75% reduction in Psoriasis Area and Severity Index (PASI 75) and 90% reduction in PASI (PASI 90) response
of patients in the entire cohort and in each of the four resulting latent classes (in the four-class model)
Entire cohort Class 1 Class 2 Class 3 Class 4 P-value Bonferroni
Patients (n) 3546 386 (109) 238 (67) 943 (266) 1979 (558) –
Mean (SD) duration of follow-up (years) 12 (10) 12 (08) 20 (08) 15 (08) 09 (11) < 0001
Mean (SD) age at baseline (years) 451 (127) 458 (126) 458 (126) 450 (123) 450 (130) 0527
Mean (SD) age at diagnosis (years) 235 (131) 239 (133) 230 (131) 235 (127) 235 (133) 0863
Sex 009
Female 1410 (398) 151 (391) 103 (433) 345 (366) 811 (410)
Male 2136 (602) 235 (609) 135 (567) 598 (634) 1168 (590)
Mean (SD) BMI (kg m–2) 311 (72) 327 (75) 311 (70) 313 (74) 307 (70) < 0001 < 0001
BMI subcategory < 0005 < 005
Underweight (BMI < 185) 34 (10) 3 (08) 1 (04) 9 (09) 21 (11)
Normal weight (BMI 185–249) 595 (168) 44 (114) 39 (164) 160 (170) 352 (178)
Overweight (BMI 250–299) 1131 (319) 109 (282) 80 (336) 288 (305) 654 (330)
Obese class I (BMI 300–349) 920 (259) 101 (262) 63 (265) 233 (247) 523 (264)
Obese class II (BMI 350–399) 487 (137) 72 (186) 28 (118) 150 (159) 237 (120)
Obese class III (BMI ≥ 40) 379 (107) 57 (148) 27 (113) 103 (109) 192 (97)
Ethnicity 0518
Asian 165 (46) 22 (57) 9 (38) 42 (45) 92 (46)
Black 19 (05) 3 (08) 1 (04) 3 (03) 12 (06)
White 3246 (915) 346 (896) 219 (920) 868 (920) 1813 (916)
Other 116 (33) 15 (39) 9 (38) 30 (32) 62 (31)
Drug < 0001 < 0001
Adalimumab 2088 (589) 191 (495) 149 (626) 488 (517) 1260 (637)
Etanercept 830 (234) 142 (368) 35 (147) 294 (312) 359 (181)
Infliximab 68 (19) 8 (21) 4 (17) 16 (17) 40 (20)
Ustekinumab 560 (158) 45 (117) 50 (210) 145 (154) 320 (162)
Smoking 0227
Current smoker 972 (274) 111 (288) 68 (286) 244 (259) 549 (277)
Past smoker 1071 (302) 105 (272) 75 (315) 301 (319) 590 (298)
Never smoked 999 (282) 94 (244) 62 (261) 244 (259) 599 (303)
NA 504 (142) 76 (197) 33 (139) 154 (163) 241 (122)
Psoriasis type
Erythrodermic 225 (63) 43 (111) 7 (29) 51 (54) 124 (63) < 0001 0003
Flexural 1434 (404) 168 (435) 136 (571) 577 (612) 1181 (597) 0369
Guttate 507 (143) 60 (155) 33 (139) 129 (137) 285 (144) 0841
Seborrhoeic 629 (177) 78 (202) 29 (122) 171 (181) 351 (177) 0081
Involved areas
Nails 2049 (578) 234 (606) 144 (605) 577 (612) 1094 (553) 0009 0290a
Palms/soles 731 (206) 109 (282) 43 (181) 198 (210) 381 (192) < 0001 0023
Scalp 2601 (733) 298 (772) 169 (710) 689 (731) 1445 (730) 0290
Past UV exposure 2679 (755) 305 (790) 186 (782) 721 (765) 512 (259) 0113
Mean (SD) baseline PASI 179 (77) 223 (95) 173 (73) 169 (67) 177 (75) < 0001 < 0001
Mean (SD) PASI 75 at 4–8 monthsb 1270 (676) 34 (134) 108 (692) 413 (686) 715 (835) < 0001 < 0001
Mean (SD) PASI 90 at 4–8 monthsb 819 (436) 7 (27) 39 (250) 142 (236) 631 (737) < 0001 < 0001
Data are n (%) unless otherwise stated. BMI, body mass index; NA, not available; UV, ultraviolet. aNot statistically significant after Bonferroni
adjustment of the P-value. bOf those with available data.
© 2021 The Authors. British Journal of Dermatology
published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists
British Journal of Dermatology (2021)
Trajectories of response in patients with psoriasis treated with biologics, N. Geifman et al. 3
classes, was selected (Figure S1; see Supporting Information).
At model convergence, each patient was assigned exclusively
to the class for which the highest posterior probability was
obtained. This class assignment was used for the subsequent
characterization of the classes.
Identification of subgroups of response to biologics
We used a LCMM, applied to the BADBIR dataset, with the aim
of identifying subgroups of patients with distinct patterns of dis-
ease over time, as measured by PASI. Patient-level variables were
then used to define the distinguishing characteristics of the sub-
groups. Full details of the model specifications and statistical
analyses can be found in Appendix S2 and Figure S1 (see Sup-
porting Information). All analyses were computed using R ver-
sion 3.2.3.12 Results are presented as the main effect with a 95%
confidence interval (CI) where possible. A significance threshold
of 5% was used for main inferences.
Sensitivity analysis in patients treated with adalimumab
A further LCMM analysis was carried out on a subset of data
from adalimumab-treated patients within BADBIR. This included
2088 patients with a total of 7429 observations (PASI measure-
ments; Figure 1). The model was specified as described above
and the best-fit model was selected using the same criteria.
Latent class analysis in clinical trial data
Access to data from four randomized, placebo-controlled trials
evaluating biologics (etanercept, secukinumab and ixek-
izumab) in chronic plaque psoriasis was requested, approved
by ClinicalStudyDataRequest.com (application ID: 1693) and
obtained through the Clinical Trial Data Transparency pro-
gramme (April 2018). The four trials are NCT01597245,
NCT01646177, NCT01365455 and and NCT01358578 (full
details in Appendix S2), and were selected for their availability
of data through the ClinicalStudyDataRequest.com platform.
We applied an LCMM to data from 2889 patients pooled
from these four clinical trials in order to identify global trajec-
tories of PASI over time, matching the analysis parameters to
those in the analysis of data from BADBIR. Full details of this
analysis can be found in Appendix S2.
A second analysis, to verify the reproducibility and consistency
of the latent class model identified in the BADBIR registry data,
was also carried out. Here, patients from the clinical trials cohort
were assigned to one of the four classes identified in BADBIR
using PASI measures at 3 and 6 months, and their trajectories
were plotted and visually compared with those obtained in the
BADBIR data (full details can be found in Appendix S2).
Human leucocyte antigen analysis
Data on HLA-C*06:02 status (i.e. the copy number of this allele)
were available for a subset of BADBIR participants enrolled in
the associated Biomarkers of Systemic Treatment Outcomes in
Psoriasis (BSTOP) study (https://bit.do/BSTOP). Using these
data on 1209 individuals, we examined associations of this bio-
marker with the trajectory classes identified in BADBIR.13,14 Full
details of this analysis are available in Appendix S2.
Ethics approvals
This study was conducted in accordance with the principles of
the 2008 Declaration of Helsinki. Samples and data were pro-
vided through the PSORT Discovery [PSORTD; approved by
Figure 1 Schematic of cohort selection for the latent class mixed modelling (LCMM) and therapy switching analyses. BADBIR, British Association
of Dermatologists Biologics and Immunomodulators Register; PASI, Psoriasis Area and Severity Index.
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National Research Ethics Service Committee London – London
Bridge (ethics approval code 14/LO/1685)], which is nested
within the BSTOP study (approved by National Research Ethics
Service Committee London – South East2; ethics approval code
11/H0802/7). Written informed consent was obtained from
all participants before enrollment.
Results
Latent class analysis identified four distinct subtypes of
response trajectory
Data on 3546 patients from BADBIR who fulfilled our inclu-
sion criteria were used to identify subgroups of patients with
similar PASI trajectories over time.11 These were patients
receiving their first biologic therapy (including the TNF inhi-
bitors adalimumab, etanercept and infliximab, and the IL-12/
IL-23 inhibitor ustekinumab; Table 1 and Figure 1). We
applied a LCMM and, based on the lowest BIC while requiring
at least 5% of patients in all resulting classes (Figure S1),15
identified four trajectory latent classes following the initiation
of any first-line biologic therapy in patients with psoriasis:
109% in class 1; 67% in class 2; 266% in class 3; and
558% in class 4. On average, all classes showed some reduc-
tion in disease severity. However, while classes 1 and 3
demonstrated a moderate but sustained reduction over time,
classes 2 and 4 demonstrated an increase in disease severity
following an initial reduction (Figure 2). Notably, the propor-
tion of responders to therapy differed between the classes with
a much lower rate of those with a 75% or greater reduction
in PASI score (PASI 75) in class 1 (134%) vs. class 4 (835%;
Table 1). Classes 2 and 3 demonstrated similar rates of PASI
75 (692% and 686%, respectively; Table 1). This finding
was consistent for a 90% or greater reduction in PASI score
(PASI 90) outcomes at 4–8 months (Table 1). To evaluate
whether these results were driven by the differential relative
effectiveness of the specific biologic therapies, a LCMM analy-
sis was conducted on the adalimumab-treated group alone,
the only single drug for which sufficient data were available.
This resulted in a good fit of the same four-class model (Fig-
ure S2; see Supporting Information), suggesting that the iden-
tified subtypes were generic rather than treatment specific.
Nevertheless, we could not rule out that responses to different
drugs would yield different trajectories.
Differences were found between the four resulting classes
in body mass index (BMI), baseline PASI and the specific
biologic therapies that patients were receiving (P < 0001;
Table 1). For example, class 1 demonstrated a higher propor-
tion of patients with erythrodermic psoriasis (P = 0003)
and/or involvement of the palms/soles (P = 0023) than the
other classes.
To determine whether any of the identified classes were
associated with differential risk of treatment failure, we exam-
ined the time to switching (i.e. from first-line biologic to a
second line of therapy) or ending therapy in each of the
resulting subgroups. This unadjusted analysis revealed that
class 2 demonstrated the overall lowest rates of switching,
while class 1 demonstrated the highest rates of switching
[hazard ratio (HR) 015 (95% CI 01–024) for class 2 vs.
class 1; HR 034 (95% CI 028–041) for class 3 vs. class 1;
HR 038 (95% CI) 032–045 for class 4 vs. class 1
(P < 0001); Figure 3].
Figure 2 Resulting classes from a four-class latent class mixed model (pink = class 1; blue = class 2; green = class 3; orange = class 4). (a)
Observed trajectories of log(PASI) over 3 years of follow-up. Plot lines represent a smoothing of the data (using a generalized additive model);
shaded areas represent the 095 confidence interval. (b) Patient trajectories in each of the resulting classes (each line represents a single patient).
PASI, Psoriasis Area and Severity Index.
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Five trajectories are identified in clinical trials
To assess the validity of the trajectory subgroups identified in
the BADBIR data, we applied the LCMM to data pooled across
four clinical trials of biologics in psoriasis, containing 36 129
PASI measurements for 2889 participants over a 35-week
observation period. This analysis identified five trajectories of
response (Figure 4). Similar to the trajectory classes identified
Figure 3 Analysis of time to switching from first-line biologic therapy in the four latent classes. Shaded areas represent the 95% confidence interval.
Figure 4 Resulting classes from a five-class latent class mixed model (pink = class 1; blue = class 2; green = class 3; orange = class 4; yellow =
class 5). (a) Observed trajectories of log(PASI) over 35 weeks of follow-up. Plot lines represent a smoothing of the data (using a generalized
additive model); shaded areas represent the 95% confidence interval. (b) Patient trajectories in each of the resulting classes (each line represents a
single patient). PASI, Psoriasis Area and Severity Index.
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in the BADBIR dataset, class 1 (193% of the cohort), and
class 3 (254%) demonstrated a moderate but sustained reduc-
tion in disease severity, with class 1 showing a slower rate of
reduction in PASI. Class 2 (156%), class 4 (165%) and class
5 (231%) all demonstrated good initial reduction in disease
severity (at varying rates) with a subsequent increase in PASI
starting from about 20 weeks onwards. Class 5 demonstrated
the highest mean (SD) BMI [311 (75); P < 0001 (Table 2)]
and had the highest proportion of patients treated with ixek-
izumab (a total of 662% of patients in class 5; P < 0001).
Over half of the patients in class 1 were treated with etaner-
cept (521%; P < 0001); patients in class 1 also tended to be
younger [mean (SD) age 433 (138) years; P = 0008].
The reproducibility and consistency of the four trajectory
classes identified in BADBIR was further assessed by assigning
participants from the clinical trials dataset to these trajectories
by using PASI ranges at 3 and 6 months. Overall, using this
approach, patterns from trial participants mimic those
observed in the matching registry-identified classes, with class
2 showing a slightly more moderate reduction in disease
severity (Appendix S2).
Genetic human leucocyte antigen biomarker associates
with trajectories of response
We next investigated whether the HLA-C*06:02 allele, which
confers the strongest genetic effect on psoriasis susceptibility
and has been shown to be associated with biologic
response,14,16 was associated with latent trajectory classes.
Based on 1209 patients included in the LCMM analysis on the
BADBIR cohort, HLA-C*06:02 was nominally associated with
membership of two LCMM classes (see Table S1 in
Appendix S2). Patients with more copies of the allele were
more likely to be in class 3: 360% of patients with two
copies of HLA-C*06:02 were in this class vs. 311% of patients
with one copy and 264% of HLA-C*06:02-negative patients
(P = 0037, unadjusted). Conversely, HLA-C*06:02 conferred
decreased likelihood of being in class 1: 133%, 94% and
80% of patients with zero, one and two copies, respectively,
were in this class (P = 0028, unadjusted). These results sug-
gest that HLA-C*06:02 status may influence patients’ trajecto-
ries. Their potential relationship with other patient-specific
features relevant to disease progression and response could be
elucidated through the study of larger genotyped cohorts.
Discussion
Previous studies of stratification in psoriasis have focused on
disease subtypes by clinical phenotype and application of
machine learning to transciptomic responses.17–19 Here we
identified four distinct, universal, trajectory subgroups, based
on longitudinal analysis of data collected within BADBIR.
Notably, these subgroups demonstrated different mean pat-
terns of change in disease severity over time and primarily dif-
fered with respect to time to, degree of and subsequent
increase in disease severity. Further, these subgroups were
characterized by various baseline clinical and genetic features.
Patients in classes 2 and 4 both demonstrated an initial
reduction in disease severity followed by an overall increase,
as defined by PASI, while those in class 3 demonstrated an ini-
tial steep reduction in disease severity followed by an overall
maintenance. Interestingly, although classes 2 and 4 both
achieved similar reductions in PASI at 18 months (Figure 2),
the pattern of reduction in disease severity differed. This sug-
gests that there may be differences in the underlying mecha-
nisms by which the disease progresses in these patients and/
or how they respond to therapy – a pattern that would not
have been captured by conventional assessments of PASI 75
Table 2 Baseline characteristics of patients in the entire clinical trial cohort and in each of the five identified latent classes
Entire cohort Class 1 Class 2 Class 3 Class 4 Class 5 P-value
Patients (n) 2889 559 (194) 451 (156) 735 (254) 478 (165) 666 (230)
Mean (SD) age at baseline (years) 449 (132) 433 (138) 459 (131) 447 (130) 453 (128) 457 (131) 0008
Mean (SD) baseline PASI 204 (70) 181 (67) 180 (71) 231 (94) 222 (88) 226 (100) < 0001
Sex < 0001
Female 897 (310) 160 (286) 113 (251) 233 (317) 137 (287) 254 (381)
Male 1992 (689) 399 (714) 338 (749) 502 (683) 341 (713) 412 (619)
Mean (SD) BMI (kg m–2) 298 (70) 282 (63) 307 (74) 288 (59) 300 (73) 311 (75) < 0001
Ethnicity 0009
Asian 367 (127) 93 (166) 67 (149) 74 (101) 58 (121) 75 (113)
Black 53 (18) 9 (16) 11 (24) 12 (16) 10 (21) 11 (16)
White 2318 (802) 437 (782) 350 (776) 616 (838) 368 (770) 547 (821)
Other 151 (52) 20 (36) 23 (51) 33 (45) 42 (88) 33 (49)
Drug < 0001
Ixekizumab – 2 weeksa 639 (221) 59 (105) 83 (184) 170 (231) 107 (224) 220 (330)
Ixekizumab – 4 weeksa 640 (221) 84 (150) 82 (182) 179 (243) 74 (155) 221 (332)
Etanercept 652 (226) 291 (521) 110 (244) 164 (223) 54 (113) 33 (49)
Secukinumab 150 mg 489 (169) 75 (134) 87 (193) 133 (181) 119 (249) 75 (113)
Secukinumab 300 mg 469 (162) 50 (89) 89 (197) 89 (121) 124 (259) 117 (176)
BMI, body mass index; PASI, Psoriasis Area and Severity Index. aInitial ixekizumab protocols, where for some patients the frequency of treat-
ment changed after the first 12 weeks.
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and PASI 90 response at a fixed timepoint. Further, therapy-
specific patterns of change in PASI over time seem to be simi-
lar for the four biologics analysed in the BABIR data (Fig-
ure S3; see Supporting Information). Nevertheless, for these
findings to be translated into a clinical tool, it may be benefi-
cial to combine some of these classes. For example, classes 3
and 4, both of which show good response, may be merged to
represent all good responders.
A high BMI in patients with psoriasis has previously been
reported to have a significant effect on their prognosis and
response to biologics, thereby reducing the rates of those
achieving PASI 75.4 Here class 1 further captured this associa-
tion of higher BMI and a reduced magnitude of change in
PASI when treated with biologics.
While HLA-C*06:02 status has been previously associated
with change in PASI response to biologics, particularly ustek-
inumab and adalimumab,14 we found only modest evidence
for an effect on longitudinal patterns of PASI in patients trea-
ted with biologics, albeit supportive of future investigation.
To assess these trajectories, in a second cohort of patients,
we applied our LCMM model to a dataset obtained from phar-
maceutical company clinical trials of biologic therapies for
psoriasis. This analysis objectively identified five trajectory
cases as the best fit; these had overall good similarity to those
identified in the registry dataset, with one low reduction, one
moderate reduction and two good PASI reduction groups
identified. There are several potential reasons why identical
results were not obtained. Firstly, the registry dataset contains
real-world data, where patients are likely to represent a more
heterogeneous and complex population such as elderly
patients, and those on polypharmacy and with multimorbidity.
Patients in clinical trials are enrolled through strict criteria.
Secondly, patients in the registry dataset, unlike in clinical tri-
als, will likely be treated with various adjuvant treatments,
such as methotrexate, to improve outcomes. Thirdly, the
specific biologics used differ between the two populations,
with only entanercept common to both. Finally, the duration
of available follow-up differed between the two datasets. Nev-
ertheless, the results obtained by our analysis of trial patients
strengthen the observations made in the registry data: (i) the
overlap between the five trajectories identified independently
in the trials dataset and the four identified in the registry data
[Figures 3 and 4, and Figure S4 (see Supporting Informa-
tion)]; and (ii) the similarity in the overall shapes of assigned
(by PASI range criteria at two timepoints) trajectories in trials
data and the initial, early-in-treatment, trajectories in the BAD-
BIR data (Appendix S2).
For the analyses presented here, patients treated with any of
the biologic therapies (in the BADBIR cohort or the clinical
trials data) were pooled together; this was done to generate
sufficiently large datasets for identification of universal trajec-
tories of disease following intitiation of biologic therapy. An
analysis of the adalimumab-treated subgroup alone – the lar-
gest available in BADBIR – resulted in the fit of a four-class
model, demonstrating robust results to those obtained by ana-
lysing the pooled BADBIR dataset (Figure S2). However,
whereas therapy-specific patterns of change in PASI over time
seem similar for the four analysed biologics (Figure S3), as
this and other registries accumulate more data, future studies
will be able to discriminate between individual biologic trajec-
tories.
We did not identify a no-change, worsening or lack-of-
response subgroup, even though such patients are encountered
in clinical practice. One possible explanation is incomplete
representation of patients whose disease worsens over time, as
these may be switched to a second biologic and our analysis
was restricted to first-line therapy. Further, informative miss-
ingness may have also affected the shape of the trajectories of
each class. We partially mitigated this through the analysis of
differences in the time to switching from first-line therapy
between the four resulting classes; this demonstrated that
patients in class 2 had a lower rate of switching, while class 1
showed higher rates (Figure 3). It is plausible that class 1 is
affected by this risk of bias, and that the PASI measures in this
group were, in reality, higher than seen in Figure 2. It is con-
ceivable that a fifth subgroup may exist in which patients
show no improvement with biologic therapy and were not
captured by our approach. Future studies should incorporate
therapy switches as an indicator of response within the sub-
group discovery algorithm to allow further validation.
Differences were found between the classes in duration of
follow-up. Individuals in class 2 had the longest mean (SD)
duration of follow-up [20 (08) years] and those in class 4
the shortest [09 (11) years]. It is conceivable that these dif-
ferences were partially driven by variation in response to ther-
apy, thus inducing informative dropout from our study for
which we could not adjust our analyses.
Interestingly, a no-change or non/low-response subgroup
was also missing from the clinical trials dataset. One possible
explanation is selection bias, which has been shown to be a
common phenomenon in clinical trials.20 This may, at least in
part, present itself in the exclusion of patients with hyperten-
sion and diabetes (known to have worse disease and poorer
responses to biologic therapy) from at least two of the trials
included in the pooled dataset. Alternatively, the absence of a
nonresponder group, from both analyses, could be the result of
the rarity of such patients who lack a primary response.
A potential introduction of bias caused by the exclusion of
patients with incomplete baseline information (247% of avail-
able patients on first-line biologic therapy with a baseline PASI
≥ 10 within the registry dataset) may have been possible; the
LCMM implementation requires complete information for any
covariates included in the model. While multiple imputation
could eliminate this potential bias, given the large number of
patients in our dataset and that missing covariate data were
likely missing completely at random, a complete case
approach remains robust.
A key strength of this study is the longitudinal nature and
quality of the BADBIR dataset, including detailed disease sever-
ity assessments and phenotypic characterizations. These rich
data enabled not only the identification of latent classes, but also
meaningful clinical characterization of these. Our findings from
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clinical trials data further strengthen these findings, and assess-
ment of potential genetic biomarkers suggests that the classes
may represent different biological mechanisms. This study is a
landmark in psoriasis research as it demonstrates the value of
data-driven approaches to using high-quality registries and clin-
ical trial data to generate hypotheses for precision medicine.
However, it should be noted that the subgroups discovered by
our analysis do not necessarily represent distinct subtypes of
psoriasis, but represent courses of disease progression following
the initiation of biologic therapy. Our approach is hypothesis
generating and requires further validation and investigation of
the underlying mechanisms. As some of the clinical and out-
come characteristics overlap between the identified trajectory
groups, it would be difficult to use these for individual patient
prediction. Nevertheless, this is the start of the process of
grouping patients based on longitudinal patterns of response.
Our next steps will involve identifying panels of genetic and
molecular biomarkers that can better predict class memberships
and response to therapy, and add these to the model.
To the best of our knowledge, this is the first study to take
a data-driven, longitudinal, statistical modelling approach for
patient stratification in psoriasis by identifying subgroups of
longitudinal patterns of disease progression. This study has
uncovered some plausible subgroups of patients with psoriasis,
based on disease course over time, which may prove, with
further causal investigation, to be distinct endotypes. These
could potentially be useful in the stratification and prediction
of response to biologic therapy, thereby improving clinical
trial design and enabling targeted research and future develop-
ments of therapies. Investigation of drug-specific trajectories,
as well as combining these LCMM classes with molecular data,
will provide putative endotypes with greater discovery poten-
tial than current clinical labels when exploring associations in
respect of biological mechanisms.
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